 Soligenix Inc NASDAQ: SNGX announced the results of its Phase 3 FLASH study evaluating HyBryte synthetic hypericin for cutaneous T-cell lymphoma CTCL had been published in the Journal of the American Medical Association JAMA Dermatology. The peer-reviewed publication. 